

2018 ICB Special Feature Review – MAIT cells

An overview on the identification of MAIT cell antigens

Lars Kjer-Nielsen^a, Alexandra J. Corbett^a, Zhenjun Chen^a, Ligong Liu^{a,b}, Jeffrey Y. W. Mak^{a,b}, Dale I. Godfrey^{a,c}, Jamie Rossjohn^{a,d,e,f,g}, David P. Fairlie^{a,b}, James McCluskey^a, Sidonia B. G. Eckle^a

Author information

1 Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria 3000, Australia.

2 Division of Chemistry and Structural Biology, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4072, Australia.

3 Australian Research Council Centre of Excellence in Advanced Molecular Imaging, The University of Queensland, Brisbane, Queensland 4072, Australia.

4 Australian Research Council Centre of Excellence in Advanced Molecular Imaging, The University of Melbourne, Melbourne, Victoria 3000, Australia.

5 Infection and Immunity Program, Biomedicine Discovery Institute, Monash University, Clayton, Victoria 3800, Australia.

6 Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria 3800, Australia.

7 Australian Research Council Centre of Excellence in Advanced Molecular Imaging, Monash University, Clayton, Victoria 3800, Australia.

8 Institute of Infection and Immunity, Cardiff University School of Medicine, Cardiff CF14 4XN, United Kingdom.

* These authors contributed equally to this work.

To whom correspondence may be addressed. E-mail: seckle@unimelb.edu.au

Abstract

Mucosal Associated Invariant T (MAIT) cells are restricted by the monomorphic MHC class I-like molecule, MHC-related protein-1 (MR1). Until 2014, the identity of the potent activating MAIT cell ligands was unknown, although it was established that MAIT cells could be activated by a broad range of bacteria and yeasts, possibly suggesting a conserved antigen. Using a combination of protein chemistry, mass spectrometry, structural biology and chemistry, we discovered MAIT cell antigens derived from folic acid (vitamin B9) and from an intermediate in the microbial biosynthesis of riboflavin (vitamin B2). While the folate derivative 6-formyl pterin (6-FP) generally inhibited MAIT cell activation, two riboflavin pathway [derivatives](#), 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil (5-OP-RU) and 5-(2-oxoethylideneamino)-6-D-ribitylaminouracil (5-OE-RU), were [very](#) potent MAIT cell agonists. [Other intermediates and derivatives](#) of riboflavin synthesis displayed [only](#) weak [or no](#) MAIT cell activation. Collectively, these studies revealed that in addition

Deleted: derivatives of the

Deleted: intermediate

Deleted: Two o

to [peptide](#) and lipid-based antigens, small [molecule](#) natural [product](#) metabolites are [also](#) ligands that can activate T cells expressing $\alpha\beta$ T cell receptors, and here we recount this discovery.

Deleted: protein

Deleted: among the

Introduction

Mucosal associated invariant T (MAIT) cells first came to attention because of their semi-invariant TCR α -chain rearrangement observed by Porcelli *et al.*¹. A rearrangement of the TRAV1-2 element juxtaposed to TRAJ33 was enriched among the CD4CD8⁺ (double negative, DN) T cell population in healthy blood donors¹. Less frequent usage of TRAJ12 and TRAJ20 segments in combination with TRAV1-2 are also present in MAIT cells²³. Homologous versions were found in DN T cells in mice, cows⁴ and sheep⁷. The $V\alpha$ -Ja rearrangement did allow for two variable amino acids encoded at the V-J junction. In addition, the repertoire of TCR β -chains paired with the semi-invariant α -chain was skewed^{1,4}, being dominated by TRBV6 and TRBV20 in humans and the murine orthologous segments of TRBV6 in mice⁴. Notably, this oligoclonality of MAIT TCR β -chains noted by Tilloy *et al.*⁴ was later confirmed⁴, who also observed a bias in the length of 11 to 14 amino acids.

The limited TCR repertoire of MAIT cells suggested that they might be restricted by a monomorphic, non-classical major histocompatibility complex (MHC) molecule¹. Lantz's team proposed the MHC class I-like molecule, MHC-related protein-1 (MR1)^{8,9}, as a candidate⁸ and later formally demonstrated MR1 as the selective and restrictive element¹⁰. MR1 is monomorphic^{8,11} and represents the most highly conserved MHC-I like gene across diverse mammalian species, with 90% sequence identity between mouse and humans as compared to 70% for classical MHC-I genes in the ligand binding site^{8,9,12}. Perhaps, it is not surprising therefore, that MR1 selects a restricted TCR repertoire. Lantz's team furthermore showed that while MR1 is present in most mammals, including marsupials, it is absent from several clades of eutherians (e.g. cat, dog, panda, ferret, rabbit, pika, and armadillo)¹². Species featuring MR1 also have a TRAV1 α -chain, with a high inter-species conservation of the CDR1 and CDR2 regions¹² and associated cross-reactivity between certain species such as human, non-human primates, bovine, rat and mouse^{13,16}, indicating the phylogenetic conservation of this T cell subset in mammals and suggesting an important physiological function.

Treiner *et al.* observed preferential location of MAIT cells at mucosal sites such as the gut lamina propria (and to a lesser extent the lung) of humans and mice. Hence, Lantz's team named the T cell subset mucosal-associated invariant T (MAIT) cells¹⁰. Recent studies also showed MAIT cells to be present at non-mucosal sites (e.g. liver)^{17,18} and they appear to be widely distributed among tissues and somewhat more prevalent in the lung than the gut (e.g. in C57BL/6 mice^{19,20}). This tendency for mature MAIT cells to take up widespread tissue residency, including mucosal localisation, as well as circulating in the blood where they can represent a high percentage of T cells in humans, suggests the moniker of MAIT cells adds to the famously confusing jargon of immunology.

Le Bourhis *et al.* and Gold *et al.* later demonstrated that a wide variety of microbes (bacteria, yeasts) (Table 1), but not viruses cause MR1-restricted MAIT cell responses. The bacterial response was dependent on the interaction between the MAIT TCR and an unknown antigen (Ag) presented by MR1, presumably either derived from bacteria or a bacteria-induced endogenous Ag²¹. Following these important studies, Lantz's team speculated that 'this ligand could be of multiple compositions, but the MR1-invariant TCR interaction would be non-discriminative, or it could be an extremely conserved compound among microbes'²²; the latter mirroring the finding of a single universal Ag for type I NKT cells².

Based on sequence comparisons by Miley *et al.* and a structure-based computation analysis by Hansen *et al.*, it was suggested that MR1 adopted an ‘MHC-I fold’^{22,23}. Indeed, it was known that MR1 associates with β 2-microglobulin (β 2m)^{23,24}, further implying MR1 possessed an MHC-I-like structure. Whilst lipid-based Ags had been proposed to bind to MR1^{25,26}, the residues lining the putative ligand binding groove were noted to be markedly different from either MHC-I or CD1d^{22,23} suggesting that MR1 did not bind peptide or glycolipid Ags. This observation led to the idea that MR1 ‘may bind a unique ligand with an anchoring scheme unlike that of other MHC class Ia or class Ib proteins’²².

The nature of the Ag(s) that activated MAIT cells was a major stumbling block in the field of MAIT cell biology. We considered that an understanding of the Ag(s) recognised by MAIT cells would help unlock the biology of these cells. In 2009, more than 15 years after the discovery of MAIT cells, our laboratories embarked on the challenge of identifying MAIT cell-stimulating MR1-bound Ag(s). This question was addressed by a multidisciplinary and highly collaborative approach that utilised a combination of methodologies, including protein chemistry, mass spectrometry, cellular biology, structural biology and chemistry. This review recounts the discoveries of vitamin B-related compounds that modulate MAIT cell function.

Main body

Establishment of experimental models providing key insights into the nature of MR1 bound antigens

As a first step in identifying MR1 ligands that activate MAIT cells, it was key to establish a reliable experimental model to assess MR1-dependent MAIT cell activation. For this purpose, genes encoding MAIT TCR α - and β -chains were introduced into a Jurkat T cell line (Jurkat.MAIT). These expressed the MAIT TCR very well and stained with a V α 7.2 mAb²⁷.

Jurkat.MAIT cells upregulated CD69 when co-incubated with bacterially infected C1R cells expressing endogenous levels of MR1. Jurkat.MAIT cell activation was augmented when C1R cells were supertransfected with the MR1 gene and overexpressed MR1 at the cell surface. Jurkat.MAIT cell activity could be blocked by the MR1 specific monoclonal antibody 26.5²⁸, verifying MR1 dependency of the observed activity. As an ongoing source of Ag(s), the bacterium *Salmonella enterica* serovar Typhimurium (*S. Typhimurium*) was investigated. *S. Typhimurium* infected C1R cells led to activation of Jurkat.MAIT cells in the co-culture assay. An advance was the discovery that culture supernatant of *S. Typhimurium* passed through a 0.2 μ m filter also activated the Jurkat.MAIT cell line in an MR1-dependent manner. The fact that the infection of an Ag presenting cell (APC) was not required for the presentation of MR1 bound Ag(s), was important as it meant that the Ag(s) of interest were likely to be secreted or shed *in vitro* and hence they were probably soluble. This key observation suggested that biochemically homogeneous and potentially soluble Ag(s) could be recovered from bacterial supernatant rather than working with highly complex bacterial lysates where the solubility of the Ag(s) was unknown.

Given the apparent solubility of the MR1 ligands in bacterial supernatant, we opted to identify their chemical nature *via* biochemical/mass spectrometry approaches. MHC and MHC-I like proteins are generally stable only in the presence of a given Ag, and thus we reasoned that the ability to sufficiently fold MR1 would only be possible in the presence of an MR1 ligand. Using Garboczi’s original protocol of MHC-I folding²⁹, we found that filtered supernatant from *S. Typhimurium* could sponsor *in vitro* folding of denatured, soluble MR1, expressed in *Escherichia coli*, in the presence of

Commented [I11]: Perhaps we could insert after 'discoveries'

²⁸, made by a team of immunologists, structural biologists and chemists from three interacting laboratories.

β 2m (Figure 1). Intriguingly, we noticed that for some samples of MR1, folded in the presence of *S. Typhimurium* supernatant, the tip of the tube was slightly yellow.

An important control at this point was to test if RPMI medium, used to culture *S. Typhimurium* prior to harvesting the supernatant, also supported folding of MR1. Surprisingly, small amounts of MR1 did fold in the presence of straight RPMI medium. This finding suggested that RPMI medium also potentially furnished a ligand that could bind to MR1. The native conformation of MR1 folded in the presence of *S. Typhimurium* culture supernatant or RPMI was confirmed by its ability to bind to the monoclonal antibody 26.5 in an enzyme linked immunosorbent assay (ELISA). The size exclusion chromatography retention time was almost overlapping with classical MHC molecules bound to peptide. Moreover, the stoichiometry with associated β 2m was 1:1 based on SDS-PAGE, exactly as observed for classical MHC molecules and β 2m³⁸. Based on these insights, we considered that mass spectrometry of folded MR1 might be a suitable approach to identify the nature of the ligands captured by MR1 for presentation to MAIT cells.

Discovery of MR1 ligands that act as competitive inhibitors of MAIT cell activation

Given that RPMI medium contains defined components and supported folding of small amounts of MR1 in the absence of bacterial culture, we initially turned to this source of material to identify MR1-captured ligands. Among the components in RPMI are flavonoid-derived vitamins, which are yellow in colour. Thus, MR1 was folded in the presence of a solution of vitamin B tablets obtained from a local pharmacy. Indeed, we recovered native MR1 from this folding experiment. When we then tested individual vitamin components in MR1 folding experiments, we observed that folic acid (vitamin B9) yielded significant amounts of native MR1. MR1 folded in the presence of folic acid or RPMI medium was then analysed by mass spectrometry, in collaboration with the laboratories of Purcell, McConville and O'Hair. In negative ion mode, this analysis revealed two mass-to-charge (m/z) species of 190.03 and 147.03 that were absent in analyses of control blank and classical peptide-MHC-I samples. Puzzlingly, the m/z 440.13 expected for folic acid ($C_{19}H_{19}N_7O_6$) by mass spectrometry, was not detected in material captured by MR1 even in the presence of folic acid. A search of the Scripps Metlin data bank revealed that the two identified species matched fragments of biopterin, which shares a pterin moiety with folic acid. It was known that folic acid photodegrades in ultraviolet light to 6-formyl pterin (6-FP, $C_{10}H_{11}N_5O_2$, m/z 190.04) and *p*-aminobenzoyl-L-glutamic acid ($C_{10}H_{11}N_2O_5$, m/z 265.08)³⁹ (Figure 2a). Subsequent collision-induced dissociation (CID) fragmentation of 6-FP revealed that the m/z 147.03 species was a product ion of the parent m/z 190.03 species. MR1 was previously observed to be expressed at low levels on the surface of cells under basal conditions³⁸. Notably, 6-FP upregulated MR1 surface expression, reminiscent of the rescue of surface expression of MHC-I in cells deficient in peptide transporter (*tap-2*)³⁸. This observation suggested that 6-FP was a *bona fide* MR1 ligand. We learnt recently that degradation of folic acid to 6-FP also occurs *in vivo*, in skin exposed to UV radiation⁴⁰.

That 6-FP was bound to MR1 was consistent with the ability to fold MR1 in the presence of pure 6-FP purchased from Schircks Laboratories. The purified product was indistinguishable from MR1 folded with folic acid, based on chromatography profiles (e.g. retention time), SDS-PAGE of purified MR1, and identical m/z 190.03 species. What was unknown however was the molecular mechanism by which MR1 captured 6-FP. Was 6-FP merely bound to the surface of MR1 in a hapten-like manner? Was there a defined antigen-binding pocket? Were there other (unidentified) ligands captured by MR1 in this process that had not been detected by mass spectrometry? The crystal structure of the MR1-6-FP complex began to resolve some of these central questions. It revealed that MR1 indeed adopted an MHC-I-fold, within which 6-FP was sequestered deep within

Commented [112]: Not sure what you are referring to here. Folic acid is in RPMI-1644. I'm not sure what "flavonoids" you are referring to.

the base of the MR1 Ag-binding cleft. Here, within the A¹-pocket, 6-FP was surrounded by a large number of aromatic residues. The structure of the MR1 Ag-binding cleft was distinct from the Ag-binding clefts of MHC and CD1, which capture peptides and lipids respectively, and demonstrated the versatility of the MHC fold to capture three classes of Ags. Indeed, the binding pocket of MR1 appeared to be ideally suited to capture small aromatic molecules. An additional surprise, revealed by the crystal structure, was that 6-FP was covalently bonded to MR1 through a Schiff base linkage (chemically known as an imine, a carbon-nitrogen double bond) formed between the formyl group of 6-FP and the side chain ε-amine of lysine 43 of MR1. Such a covalent interaction between an Ag and Ag-presenting molecule had not been observed previously, and has subsequently been shown to act as a ‘molecular switch’ that enables MR1 to egress from the endoplasmic reticulum²⁵.

Whilst 6-FP was presented by MR1, it did not activate MAIT cells, and neither did other ligands from the folate pathway. This suggested that MAIT cells must be activated by a different ligand. It was also observed that MAIT cell activation was inhibited when both non-activating 6-FP and activating *S. Typhimurium* supernatant or synthetic ligands were added together to Jurkat.MAIT and C1R.MR1 cells^{26,27}. The inhibitory effect was specific to 6-FP and the MAIT-MR1 interaction and not observed with other pteridine analogues of folate, such as 6,7-dimethylpterin, 6-hydroxymethylpterin, or 6-hydroxymethyl-7,8-dihydropterin.

In later experiments, we identified an analogue of 6-FP, *N*-acetyl-6-formylpterin (Ac-6-FP) (Figure 2b), which also engendered efficient folding of MR1. Ac-6-FP was more potent than 6-FP in inhibiting activation of Jurkat.MAIT cells by *S. Typhimurium* supernatant in the presence of C1R.MR1 cells (unpublished). In much later experiments we showed that repeated intranasal delivery of Ac-6-FP to C57BL/6 mice inhibited MAIT cell activation by stimulatory Ags in the lungs of mice²⁸. Thus, we had identified 6-FP and Ac-6-FP as small molecule antagonists, capable of blocking activation of MAIT cells by ligands from bacteria via competitive inhibition. However, the activating ligand in *Salmonella* supernatant remained elusive.

Deleted: activating

Discovery of MR1 bound antigens that activate MAIT cells

Identification of the riboflavin biosynthesis pathway as the source of MAIT cell antigens

The discovery that a vitamin B9 degradation product, 6-FP, was captured from RPMI and acted as a non-stimulatory MAIT cell Ag, led us to hypothesise that the active MR1-bound ligand may be competed from MR1-binding by the abundance of 6-FP in culture supernatants. Thus, we reasoned that the capture and identification of activating Ag(s) by MR1 might be more efficient if culture conditions minimized the levels of folate in the medium. This was achieved by growing *S. Typhimurium* in a minimal medium (M9), that lacked vitamin B9. Indeed, supernatant of *S. Typhimurium* grown in M9 media, but not the control M9 media alone, activated Jurkat.MAIT cells in the presence of C1R.MR1 cells and engendered folding of MR1 with β2m. High resolution mass spectrometry of the ligand, subsequently eluted from MR1, allowed determination of the *m/z* 329.11 in negative ion mode. Upon examining isotopic mass distribution in the mass spectrometry experiments, the ligand could be unambiguously assigned to the formula C₁₂H₁₆N₄O₂. A database search of compounds with this composition and *m/z* yielded no match, but some ribityllumazine compounds from the riboflavin (vitamin B2) biosynthetic pathway were close, such as 7-hydroxy-6-methyl-8-D-ribityllumazine (RL-6-Me-7-OH, C₁₂H₁₆N₄O₂, *m/z* 327.0946 in negative ion mode) and 6,7-dimethyl-8-D-ribityllumazine (RL-6,7-diMe, C₁₃H₁₈N₄O₂, *m/z* 325.1153 in negative ion mode) (Figure 3). It was noted from two key studies^{29,30} that only microbes that activated MAIT cells possessed a complete riboflavin biosynthetic pathway (Table 1)²⁹. Thus, it became apparent that a riboflavin metabolite may be an activating MAIT cell ligand.

Deleted: the dominant ligand

The gold standard in assigning a given Ag to T cell activation is the ability to recapitulate candidate Ag activity with pure, structurally well-defined compounds produced by chemical synthesis. Whilst RL-6-Me-7-OH and RL-6,7-diMe were unstable and challenging to synthesize, they were obtained in sufficient quantities for functional assays. Both compounds specifically activated Jurkat.MAIT cells in the presence of C1R.MR1 cells in an MR1-dependent manner, although the levels of activation were very modest, and much lower than the activity observed for *S. Typhimurium* supernatant³⁰.

Structural basis of MAIT TCR recognition of MR1-RL-6-Me-7-OH versus MR1-6-FP

The molecular basis for the lack of activation of MAIT cells by 6-FP in the face of activation by riboflavin-derived ligands was resolved in crystal structures of the MAIT TCR-MR1-Ag ternary complexes with 6-FP and RL-6-Me-7-OH. **In order to improve the inefficient folding of MR1 with our synthetic ligands, we had also made use of an unexpected finding, namely that the lysine to alanine (K43A) mutant, MR1-K43A could be folded with β2m in the absence of ligand (designated "empty" MR1-K43A). RL-6-Me-7-OH could thus also be loaded into "empty" MR1-K43A and its structure determined.** The high resolution to which these MAIT TCR ternary complexes were resolved allowed for unambiguous assignment of the small molecule Ags within these complexes.³⁰ These ternary structures revealed that MR1 could capture RL-6-Me-7-OH and 6-FP within the MR1 cleft. **Although 6-FP formed a covalent Schiff base adduct with MR1, whereas RL-6-Me-7-OH cannot and was instead non-covalently bound, the overall docking topologies of the TCRs onto MR1 bound to these ligands were very similar.** The ribityl moiety of RL-6-Me-7-OH was directly contacted via a hydrogen bond with the highly conserved Tyr 95 of the MAIT TCR α-chain. In contrast, there were no direct TCR contacts with 6-FP, which lacks the ribityl moiety. This observation provided a mechanism for the activation of MAIT cells by RL-6-Me-7-OH, as compared to the inhibition by 6-FP. It also suggested a basis for the dominant selection of TRAJ33 by MAIT TCRs as this was one of only three Jα segments that contained a Tyr 95α. Together with the increased affinity of MAIT TCR for MR1 presenting the riboflavin metabolite over the folate ligand, this provided the first molecular insights into MAIT cell agonism, as well as definitive insights into the nature of the invariant MAIT TCR usage³⁰.

rRL-6-CH₂OH as a candidate MAIT cell antigen

RL-6-Me-7-OH and RL-6,7-diMe **did not match the formula C₇H₉N₂O₄, unambiguously assigned to the Ag derived from *S. Typhimurium* through isotopic mass distribution in mass spectra. Three new compounds could be attributed to this formula, but were not previously described in riboflavin biosynthesis (Figure 4). They were a dihydrogen-reduced form of the key vitamin B2 biosynthesis metabolite RL-6-Me-7-OH (abbreviated rRL-6-Me-7-OH); a dihydrogen-reduced form of 6-hydroxymethyl-8-D-ribityllumazine (called rRL-6-CH₂OH or rRL-6HM), or 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil (abbreviated 5-OP-RU), that was expected to be far too unstable to survive in water. Attempts to preserve synthetic rRL-6-Me-7-OH failed due to its extremely facile oxidation to RL-6-Me-7-OH, but rRL-6-CH₂OH could be synthesized from the key intermediate 5-amino-6-D-ribitylaminouracil (5-A-RU) by condensation with 1,3-dihydroxyacetone. Synthetic rRL-6CH₂OH, matching the m/z species of 329.11 identified from *Salmonella* supernatant, seemed to potently activate MAIT cells in an MR1-dependent manner.³⁰ Importantly, fluorochrome-coupled tetramers of MR1-K43A, apparently loaded with this rRL-6-CH₂OH, stained human MAIT cells permitting their characterisation; and supporting the notion that we were on the right track in unlocking the ligand biology of MAIT cells. Later we realized that only a late eluting trace contaminant, identified in liquid chromatography fractions of synthetic rRL-6CH₂OH, was actually**

Commented [I13]: I have switched a few bits (green) around and altered key wording in this and the next section to achieve the right meaning.

Moved (insertion) [1]

Field Code Changed

Deleted: , and that

Deleted: form a Schiff base with MR1

Deleted: . Whilst

Deleted: -

Deleted: Ag

Deleted: .

Deleted: t

Deleted: by

Deleted: activation

Deleted: The low MR1 folding yields with

Deleted: , the instability of these complexes and their comparably low level of MAIT cell activation indicated that

Deleted: following

Deleted: spectrometry

Deleted: At the time, we focused on 2 entirely

Deleted: that

Deleted: . Neither had

Deleted: been

Deleted: .

Formatted: Not Highlight

Deleted: .

Deleted: The possible candidates were

Deleted: or

Deleted: also

Deleted: .

Deleted: As it turned out, we later realized there was a thi

Deleted: .

Deleted: but this

Deleted: lthough a

Deleted: the

Deleted: stable

Deleted: s

Deleted: and so we persevered with this compound. The s

Deleted: ed

Deleted: and

Deleted: d

Formatted: Superscript

Moved (insertion) [2]

Field Code Changed

Deleted: thus further cementing

responsible entirely for folding MR1. We aimed to determine the crystal structure of MR1 loaded with synthetic rRL-6-CHOH and complexed to a MAIT TCR. We were able to load rRL-6-CHOH into “empty” MR1-K43A and determined the crystal structure in complex with a MAIT TCR. To our astonishment, instead of the expected two-ring structure of rRL-6-CHOH, the electron density indicated that a one-ring structure was present. However, we remained puzzled at how this ligand was derived from riboflavin biosynthesis.

A genetic approach showing that the riboflavin pathway was required for MAIT cell activation

Given the challenges of biochemically nailing the riboflavin synthesis pathway as furnishing the precursor of physiological activating MAIT cell ligands, we turned to a genetic approach to understand the origin of MAIT cell activating ligands from microbial riboflavin synthesis (see ⁴⁰ and Figure 3). Most of the work defining this pathway was performed using *Bacillus* spp.. In these, and other Gram-positive bacteria, including *Lactococcus* spp., the *Rib* genes are grouped into a single, 4-gene operon (ribGBAH), which is under transcriptional regulation through a riboswitch, such that riboflavin or flavin mononucleotides (FMN) downregulate the further production of riboflavin ^{40,41}.

Two recent papers demonstrate MAIT cell activation by *Streptococcus pneumoniae* and show that the riboflavin biosynthesis pathway is highly conserved amongst pneumococci and also present in other *Streptococcus* spp. ^{42,43}, but lacking from 2400 *S. pyogenes* strains ⁴⁴, consistent with a previously reported lack of MAIT cell activation ³¹. In 571 pneumococci the genes (“*rib* DEAH”, equivalent to “*rib* GBAH”) were found clustered together in a highly conserved operon ⁴⁵.

Other bacteria, such as the Gram-negative *E. coli* and *Salmonella* spp., have their riboflavin synthesis enzyme genes dispersed throughout the genome. Production of riboflavin is also regulated in these species, through a number of mechanisms ⁴⁶. Furthermore, although an essential pathway for many organisms, evolution has resulted in many gene variants (genetic solutions), including in some bacteria and plants where *ribA* and *ribB* are combined into a bifunctional enzyme, *ribAB*, and in yeast and plants whereby the pathway differs in this reaction step ^{44a}. A further complication is that the enzyme nomenclature also differs among bacteria. The details of riboflavin synthesis and its regulation are complex and still emerging, with the recent discovery of the 5-A-RU 5'-phosphate phosphatase in *Arabidopsis thaliana* ⁴⁷, completing the pathway.

Adding riboflavin to bacterial cultures of *S. Typhimurium* inhibited the activation of Jurkat.MAIT cells by these culture supernatants ³⁹. Consistent with our findings, exogenous riboflavin has also recently been shown to decrease activation of MAIT cells by *Streptococcus pneumoniae* ^{42,43}. In the *S. Typhimurium* genome, *ribD* and *ribH* are grouped together – thus initial experiments demonstrating the requirement for the riboflavin pathway in the production of MAIT cell stimulatory Ags used a mutant lacking both genes. *S. Typhimurium* SL1344 Δ *ribDH* ³⁹, and later *S. Typhimurium* BRD509 Δ *ribDH* ³⁹, to demonstrate markedly decreased MAIT cell activation, and this activity could be reconstituted by addition to the mutants of *ribDH* expressed from a plasmid.

To pinpoint the specific step in the pathway leading to production of MAIT cell-stimulating Ag(s), individual gene deficient strains were needed. Thus, the *Lactococcus lactis* CB013 roseoflavin resistant mutant ³⁸, which constitutively expresses riboflavin and lacks the feedback mechanisms that complicated earlier attempts, was used to construct a set of gene deficient bacteria lacking individual *rib* genes (generated by our collaborator, Jennifer Mahoney). In these experiments ³⁹, *ribA* and *ribG* mutant strains (*ribD* in *Salmonella*) clearly abrogated MAIT cell activation, whereas *ribB* and *ribH* did not. Additionally, alongside results from wt *S. Typhimurium* (+ve for 329.11 species) and *Enterococcus faecalis* (-ve), the ability of supernatant from these mutants to drive MR1 folding and

Deleted: (Kjer-Nielsen et al., 2012).

Formatted: Highlight

Deleted:

Deleted: thus

Moved up [1]: In order to improve the inefficient folding of MR1 with our synthetic ligands, we made use of an unexpected finding, namely that the lysine to alanine (K43A) mutant, MR1-K43A could be folded with β 2m in the absence of ligand (designated “empty” MR1-K43A). RL-6-Me-7-OH could thus be loaded into “empty” MR1-K43A and its structure determined.

Deleted: sis

Deleted: of

Deleted: with

Deleted: In order to improve the inefficient folding of MR1 with our synthetic ligands, we made use of an unexpected finding, namely that the lysine to alanine (K43A) mutant, MR1-K43A could be folded with β 2m in the absence of ligand (designated “empty” MR1-K43A). RL-6-Me-7-OH could thus be loaded into “empty” MR1-K43A and its structure determined. We

Formatted: Highlight

Formatted: Highlight

Formatted: Highlight

Deleted: hls

Formatted: Highlight

Formatted: Highlight

Moved up [2]: Importantly, fluorochrome-coupled tetramers of MR1-K43A loaded with rRL-6-CHOH stained human MAIT cells permitting their characterisation, thus further cementing the notion that we were on the right track in unlocking the ligand biology of MAIT cells.

identification of the m/z 329.11 species by mass spectrometry correlated with activity in Jurkat.MAIT cell activation assays³⁹. Taken together, these experiments definitively pinpointed the key metabolite necessary to generate activating MAIT cell ligands as 5-amino-6-D-ribitylaminouracil (5-A-RU). These studies have now been recapitulated for *E. coli* and *S. pneumoniae* by other groups, and also demonstrate the requirement for *ribD/G* in these bacteria^{43,49}.

Multiple strands of evidence came together in an overlapping sequence of discoveries to identify the MAIT cell Ag formed from 5-A-RU. The collective evidence leveraged the contributions of all three laboratories collaborating on the project. These included insights from the old biochemical literature and associated data, X-ray crystallographic structures of MR1-Ag complexes bound to a MAIT TCR and fundamental chemistry considerations.

Clues from the biochemical and chemical literature

While 5-A-RU alone appeared to stimulate Jurkat.MAIT cells, its m/z in negative ion mode ($C_{12}H_{16}N_2O_6$, m/z 275.09) was about 54 units smaller than the m/z of the Ag derived from *S. Typhimurium*, 329.11. Also, we could readily fold MR1 in the presence of 5-A-RU, which was colourless but became intensely yellow on storage, matching the faint yellow colour occasionally observed when MR1 was folded in the presence of *Salmonella* supernatant. However, mass spectrometry of the resulting purified MR1-Ag, gave an m/z 315.09 (negative ion mode), or 40 units larger than the m/z of 5-A-RU and 14 units smaller than the m/z of the Ag derived from *S. Typhimurium*, 329.11. Thus, we were left with a biochemical puzzle.

Further molecular insights came from reviewing the literature on 5-A-RU as part of the riboflavin synthesis. A key publication from Bacher's team predicted that *en route* to producing the ribityllumazine RL-6,7-diMe during riboflavin synthesis, 5-A-RU forms a Schiff base with 3,4-dihydroxy-2-butanone-4-phosphate (3,4-DH-2-B-4-P) to yield an unstable ring-opened pyrimidine intermediate, 5-(1-methyl-2-oxopropylideneamino)-6-D-ribitylaminouracil (5-MOP-RU, $C_{12}H_{16}N_2O_6$, m/z 343.13)⁵⁰. Bacher's team also showed, that the reaction of the riboflavin pathway catalysed by the lumazine synthase (RibH) could also occur spontaneously, in the absence of any enzymatic catalysis. Hence, both 3,4-dihydroxy-2-butanone-4-phosphate and upon dephosphorylation, 2,3-butanedione, could form a Schiff base with 5-A-RU^{50,51}. This suggested that other small molecules might spontaneously undergo similar reactions during *in vitro* folding, one of which might generate the dominant m/z 329.11 product derived from *S. Typhimurium* culture supernatant and another the m/z 315.09 species observed following folding of MR1 in the presence of 5-A-RU. Indeed, methylglyoxal, lacking a methyl group compared to 2,3-butanedione, would be expected to form a Schiff base with 5-A-RU to yield 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil (5-OP-RU, $C_{12}H_{16}N_2O_6$), matching the m/z of 329.11 in negative ion mode, a compound theoretically generated *en route* to creating 7-methyl-8-D-ribityllumazine (RL-7-Me) (Figure 5). Similarly, we reasoned that it was glyoxal, lacking two methyl groups compared to 2,3-butanedione, that had formed a Schiff base with 5-A-RU to yield 5-(2-oxoethylideneamino)-6-D-ribitylaminouracil (5-OE-RU, $C_{11}H_{14}N_2O_6$). By analogy with 5-OP-RU, 5-OE-RU was theoretically generated *en route* to creating 8-D-ribityllumazine (RL) (Figure 5).

Aiming to generate MR1 loaded with 5-OP-RU, we initially folded MR1 in the presence of equimolar amounts of 5-A-RU and methylglyoxal. Whilst the dominant species remained m/z 315.09 we now observed a minor m/z 329.11 species. Using a molar excess of methylglyoxal (an arbitrary molar excess of over 300-fold was chosen), we did however solely identify m/z 329.11. MR1 tetramers with both species effectively stained MAIT cells³⁹, and unpublished. Moreover, when re-examining mass spectrometry of MR1 folded in the presence of *Salmonella* supernatant we observed a minor m/z 315.09 next to the dominant m/z of 329.11. Also folding of MR1 in the presence of *E.*

Commented [I14]: I have added the word chemistry here and removed the separate heading below, since there were no "chemistry considerations" described.

Deleted: *stry*

Deleted: of

Deleted: colour

Deleted: biochemical

Deleted: when

Deleted: It did not escape our attention that this resembled the one-ring ligand seen in the crystal structure containing MR1-K43A loaded with the synthesis of rRL-6-CHOH.

coli (DH5 α) supernatant gave a distinct, more abundant, m/z 315.09 in comparison to a m/z 329.11 species³⁹, consistent with the findings of others³⁹. Thus, we reasoned that both the m/z 315.09 and 329.11 species were likely acting as potent, natural MAIT cell Ags. Notably, both glyoxal and methylglyoxal are formed from a number of metabolic pathways, including mammalian and bacterial glycolysis (Wang and Ho, 2012) and glyoxal is widely abundant as it is produced industrially as a precursor to many products (Mattiotta and Blanc, 2000). The almost ubiquitous presence of glyoxal explained the presence of the m/z 315.09 species in refolds of MR1 with pure 5-A-RU alone, whereby folding yields could be increased by adding additional glyoxal.

The structural basis for ligand selectivity by MR1

To understand the basis for ligand selectivity by MR1, we determined high resolution crystal structures of the MAIT TCR in complex with MR1 folded in the presence of 5-A-RU and methylglyoxal or glyoxal³⁹. In both structures the electron density at the site of the Ag binding pocket was unambiguously matching 5-OP-RU and 5-OE-RU, respectively. Analogous to 6-FP, the carbonyl groups derived from methylglyoxal and glyoxal when forming 5-OP-RU and 5-OE-RU, respectively, extended to Lysine 43 of MR1 to form a Schiff base. The Ags were further stabilized in MR1 through an extensive hydrogen-bonding network. As with RL-6-Me-7-OH, the ribityl chain of 5-OP-RU and 5-OE-RU were also directly contacted by the Tyr 95 of the MAIT TCR α -chain and an additional water-mediated hydrogen bond was mediated by the CDR3 β loop of the TCR. The affinities of MR1-5-OP-RU or MR1-5-OE-RU complexes with MAIT TCRs, measured by surface plasmon resonance, were comparable to those with conventional TCRs recognizing MHC-peptide complexes (K_{deq} ~ 0.5–10 μ M)^{39,42}.

When we determined the crystal structure of MAIT TCR complexed with the mutant MR1-K43A loaded apparently with synthetic rRL-6-CHOH, we found that the Ag bound to MR1 was instead 5-OP-RU³⁹. This was consistent with HPLC chromatograms of synthetic rRL-6-CHOH, which showed a late eluting trace contaminant that proved to be entirely responsible for folding MR1. The retention time matched that of the Ag derived from *S. Typhimurium*, under the same chromatographic conditions. Given that Schiff base formation was not possible with MR1-K43A, it became clear that a Schiff base was not obligatory for ligation of 5-OP-RU. Other interactions with MR1 were evidently sufficient for MR1 to ligate the Ag and prevent its cyclisation to a ribityllumazine. However, the lack of a covalent Schiff base bond to MR1 impacted profoundly on the stability of the Ag-MR1 complex, which was markedly reduced (17°C lower half-maximum melting temperature by thermostability)³⁹. Unlike 5-OP-RU, 5-A-RU alone, however, could not be loaded into MR1-K43A (unpublished).

Neither 5-OP-RU nor 5-OE-RU were previously known to exist naturally, and they are the first examples of organic heterocycles as T cell Ags. However, they are also chemically very unstable in water where they cyclise to ribityllumazines in minutes at 37°C. A synthesis was therefore devised to produce 5-OP-RU and 5-OE-RU in dimethylsulfoxide, where they were indefinitely stable and could be extensively characterized in solution by NMR spectroscopy³⁹. Later this method was further optimised to provide a reliable source of pure MAIT cell Ags for studying their chemical reactivity³⁹ and MAIT cell activation *in vitro* and *in vivo*³⁹.

In summary, instead of capturing the thermodynamically more stable ribityllumazines, MR1 prefers to sequester a thermodynamically unstable pyrimidine intermediate formed transiently through condensation of compounds arising from two distinct metabolic pathways, 5-A-RU from the bacterial biosynthesis of riboflavin and methylglyoxal/glyoxal from bacterial or mammalian

Deleted: ⁴
*Fundamental chemistry considerations*⁴

Deleted: was instead 5-OP-RU that was

Deleted: the finding that a trace

Deleted: amount of 5-OP-RU was often present in, or produced in stored, synthetic samples of rRL-6-CHOH³⁹.

glycolysis. This confirmed our hypothesis that the way MR1 Ags are created and captured is unique amongst T cell Ags³⁹.

Reflections on MR1 antigen diversity

Classical MHC-I molecules have evolved under strong positive, diversifying, selection³⁴ causing them to be highly polymorphic. Whilst not formally investigated, MR1 appears monomorphic³¹ and the high conservation of the MR1 Ag binding site across species indicates that it has evolved under strong negative, purifying, selection³². Early on, this, together with the semi-invariant MAIT TCR usage composed of a nearly invariant TCR α -chain and a limited array of TCR β -chains, led to the hypothesis that MAIT cells might recognise a single Ag or a limited number of Ags^{1,6,10}. Following the finding that MAIT cells recognise a broad array of both bacteria and yeast species, the hypothesis was further refined: ‘MAIT cell Ags were either extremely conserved between microbial species or TCRs would be non-discriminative’³³, contrasting with the exquisite fine-specificity of conventional TCRs recognising structurally related peptide Ags³⁴.

Indeed, we discovered several activating MAIT cell Ags and they fit both hypotheses: There is substantial evidence that MR1 focuses on a metabolic pathway that is conserved between many microbial species, namely the riboflavin pathway derived pyrimidine³⁵ and ribityllumazine^{30,36} Ags. Given the various versions of the riboflavin pathway, and their modifications, variants of 5-A-RU and ribityllumazines might exist. Also, physiological by-products other than methylglyoxal and glyoxal might be capable of forming a Schiff base with both MR1 and 5-A-RU, thus forming Ags around a generic scaffold that could differ based on the microbe as previously described for 5-OP-RU versus 5-OE-RU³⁹, or metabolic stage of the microbe or host that might also differ in different tissues. At the same time, whilst related, pyrimidines and ribityllumazines are structurally different yet both recognised by the same MAIT TCRs in a pattern-recognition like manner³⁷.

Whilst MR1 likely presents a limited number of Ags, this is matched with a large precursor frequency of responding MAIT cells, that exceeds the number of T cells available to recognise any peptide-MHC Ag³⁸, allowing for a rapid powerful response. Notably, there is appreciable variation in the MAIT TCR β -chain repertoire, especially in the CDR3 β loop, which also displays remarkable structural plasticity when fine-tuning MR1 recognition in an Ag-dependent manner³⁷. Furthermore, the TCR α -chain can feature diversity beyond the canonical TRAV1-2-TRAJ33 rearrangement, where frequently also TRAJ12 and 20 are used^{4,5,37} but also other TRAJ segments including some that lack the Tyr 95 residue³⁸, that was shown to be pivotal in MAIT cell activation, hydrogen bonding with the ribityl moiety of activating Ags^{4,5,27,36,37,39,51,59}. Furthermore diverse TRAV1-2 TCRs with various reactivity patterns have been described: (i) some reacted like classical MAIT TCRs with MR1-5-OP-RU tetramers only³⁷; (ii) others reacted with both tetramers with folic acid derived ligands and 5-OP-RU³⁷, or in one case responded to both riboflavin pathway derived Ags and a riboflavin deficient microbe (*S. pyogenes*)⁶⁰ and as such overlapped with the classical MAIT cell reactivity; (iii) a third type reacted with tetramers with folic acid derived ligands only³⁷ or responded to self-Ags only⁶¹ and as such was not overlapping with the classical MR1-5-OP-RU reactive T cell subset. Gold *et al.*³⁸ also observed distinct MAIT TCR repertoire mobilization in response to diverse pathogens that could reflect the existence of discrete pathogen-associated Ags presented by MR1. TRAV1-2 MR1 restricted T cells, as investigated by Gherardin *et al.*, also lacked the MAIT cell lineage-specific transcription factors PLZF and ROR γ t and were heterogeneous for T-bet, suggesting developmental and functional differences compared to the TRAV1-2 MAIT cells³⁷.

Thus, additional natural Ags presented by MR1 might exist and be recognised by TCRs in a subset specific manner. This is also further supported by our observation that MR1 has the versatility and

plasticity to accommodate structurally diverse drugs, drug metabolites and drug analogues in the A²-pocket³⁸. In addition, Ags might bind in the F¹-pocket of MR1, mirroring our observation of crystallisation buffer molecules in the F¹-pocket of TCR-MR1-Ag crystal structures³². It will be important to identify the chemical structures, metabolic origin and physiological relevance of any newly identified natural Ags, requiring careful functional, biochemical and structural characterisation.

Where to next

The discovery of the 5-OP-RU and 5-OE-RU [as very potent](#) Ags and development of MR1-tetramers^{5,39}, now available from the National Institutes of Health, U. S. A., have opened up the field to start elucidating the roles of MAIT cells in anti-microbial immunity^{19,42,64}, [in](#) sensing of metabolic changes such as in cancer stress and cell damage^{61,65}, as well as in immunopathology^{66,68}. The tetramers have also allowed further characterisation of the phenotypic identity of MAIT cells, with various subsets. Furthermore, their development and individual and age specific differences are being investigated^{69,71}. There is still much to be understood about the identity and functions of MAIT cells, including their roles in immunity and disease, which in our experience seem much harder to nail.

Figure legends

Figure 1

Schematic of ‘Ag-fishing’ or bioprospecting, whereby denatured MR1 and β m serve as ‘bait’ to ‘fish’ potential Ags, such as 5-OP-RU and 6-FP, from complex metabolic mixtures in bacterial supernatants.

Figure 2

MR1 ligands that act as competitive inhibitors of MAIT cell activation. a) Photodegradation of folic acid in ultraviolet light to 6-formylpterin and *p*-aminobenzoyl-L-glutamic acid. b) Acetyl-6-formylpterin, a synthetic analogue of 6-formylpterin. Chemical structures, formulas and *m/z* in negative ion mode are indicated.

Figure 3

Riboflavin biosynthesis pathway. *ribH*, lumazine synthase; X, hypothetical phosphatase. Chemical structures are indicated.

Figure 4

Structures of three regioisomers (*m/z* 329.11, negative ion mode) that have the same molecular formula C₁₂H₁₀N₂O: rRL-6-Me-7-OH and rRL-6-CH₂OH and that can be derived non-enzymatically from the key vitamin B2 biosynthesis intermediate 5-A-RU.


Figure 5

Formation of pyrimidines and ribityllumazines from condensation of small metabolites with 5-A-RU. Chemical structures are indicated.

2018 ICB Special Feature Review – MAIT cells

Acknowledgements

This work was supported by Program Grants 1016629 and 1113293 and Project Grants 1062889, 1125493, and 1120467 from the National Health and Medical Research Council of Australia and by a Merieux Research Grant. A.J.C. is supported by an Australian Research Council Future Fellowship. D.I.G. and D.P.F. are supported by National Health and Medical Research Council Senior Principal Research Fellowships. J.R. is supported by an Australian Research Council Laureate Fellowship. S.B.G.E. is supported by an Australian Research Council Discovery Early Career Researcher Award Fellowship.



References

1. Porcelli S, Yockey CE, Brenner MB, Balk SP. Analysis of T cell antigen receptor (TCR) expression by human peripheral blood CD4-8- alpha/beta T cells demonstrates preferential use of several V beta genes and an invariant TCR alpha chain. *The Journal of experimental medicine* 1993; **178**(1): 1-16.
2. Gold MC, Cerri S, Smyk-Pearson S, Cansler ME, Vogt TM, Delepine J *et al.* Human mucosal associated invariant T cells detect bacterially infected cells. *PLoS biology* 2010; **8**(6): e1000407.
3. Gold MC, Lewinsohn DM. Co-dependents: MR1-restricted MAIT cells and their antimicrobial function. *Nature reviews. Microbiology* 2013; **11**(1): 14-9.
4. Lepore M, Kalinichenko A, Colone A, Paleja B, Singhal A, Tschumi A *et al.* Parallel T-cell clonal expansion and deep sequencing of human MAIT cells reveal stable oligoclonal TCRbeta repertoire. *Nature communications* 2014; **5**: 3866.
5. Reantragoon R, Corbett AJ, Sakala IG, Gherardin NA, Furness JB, Chen Z *et al.* Antigen-loaded MR1 tetramers define T cell receptor heterogeneity in mucosal-associated invariant T cells. *The Journal of experimental medicine* 2013; **210**(11): 2305-20.
6. Tilloy F, Treiner E, Park SH, Garcia C, Lemonnier F, de la Salle H *et al.* An invariant T cell receptor alpha chain defines a novel TAP-independent major histocompatibility complex class Ib-restricted alpha/beta T cell subpopulation in mammals. *The Journal of experimental medicine* 1999; **189**(12): 1907-21.
7. Goldfinch N, Reinink P, Connelley T, Koets A, Morrison I, Van Rhijn I. Conservation of mucosal associated invariant T (MAIT) cells and the MR1 restriction element in ruminants, and abundance of MAIT cells in spleen. *Veterinary research* 2010; **41**(5): 62.
8. Hashimoto K, Hirai M, Kurosawa Y. A gene outside the human MHC related to classical HLA class I genes. *Science (New York, N.Y.)* 1995; **269**(5224): 693-5.
9. Riegert P, Wanner V, Bahram S. Genomics, isoforms, expression, and phylogeny of the MHC class I-related MR1 gene. *Journal of immunology (Baltimore, Md. : 1950)* 1998; **161**(8): 4066-77.
10. Treiner E, Duban L, Bahram S, Radosavljevic M, Wanner V, Tilloy F *et al.* Selection of evolutionarily conserved mucosal-associated invariant T cells by MR1. *Nature* 2003; **422**(6928): 164-9.
11. Parra-Cuadrado JF, Navarro P, Mirones I, Setien F, Oteo M, Martinez-Naves E. A study on the polymorphism of human MHC class I-related MR1 gene and identification of an MR1-like pseudogene. *Tissue antigens* 2000; **56**(2): 170-2.
12. Boudinot P, Mondot S, Jouneau L, Teyton L, Lefranc MP, Lantz O. Restricting nonclassical MHC genes coevolve with TRAV genes used by innate-like T cells in mammals.

2018 ICB Special Feature Review – MAIT cells

Proceedings of the National Academy of Sciences of the United States of America 2016; **113**(21): E2983-92.

13. Greene JM, Dash P, Roy S, McMurtrey C, Awad W, Reed JS *et al.* MR1-restricted mucosal-associated invariant T (MAIT) cells respond to mycobacterial vaccination and infection in nonhuman primates. *Mucosal immunology* 2017; **10**(3): 802-813.
14. Huang S, Martin E, Kim S, Yu L, Soudais C, Fremont DH *et al.* MR1 antigen presentation to mucosal-associated invariant T cells was highly conserved in evolution. *Proceedings of the National Academy of Sciences of the United States of America* 2009; **106**(20): 8290-5.
15. Lopez-Sagaseta J, Dulberger CL, Crooks JE, Parks CD, Luoma AM, McFedries A *et al.* The molecular basis for Mucosal-Associated Invariant T cell recognition of MR1 proteins. *Proceedings of the National Academy of Sciences of the United States of America* 2013; **110**(19): E1771-8.
16. Lopez-Sagaseta J, Dulberger CL, McFedries A, Cushman M, Saghatelian A, Adams EJ. MAIT recognition of a stimulatory bacterial antigen bound to MR1. *Journal of immunology (Baltimore, Md. : 1950)* 2013; **191**(10): 5268-77.
17. Dusseaux M, Martin E, Serriari N, Peguillet I, Premel V, Louis D *et al.* Human MAIT cells are xenobiotic-resistant, tissue-targeted, CD161hi IL-17-secreting T cells. *Blood* 2011; **117**(4): 1250-9.
18. Tang XZ, Jo J, Tan AT, Sandalova E, Chia A, Tan KC *et al.* IL-7 licenses activation of human liver intrasinusoidal mucosal-associated invariant T cells. *Journal of immunology (Baltimore, Md. : 1950)* 2013; **190**(7): 3142-52.
19. Chen Z, Wang H, D'Souza C, Sun S, Kostenko L, Eckle SB *et al.* Mucosal-associated invariant T-cell activation and accumulation after in vivo infection depends on microbial riboflavin synthesis and co-stimulatory signals. *Mucosal immunology* 2016.
20. Rahimpour A, Koay HF, Enders A, Clanchy R, Eckle SBG, Meehan B *et al.* Identification of phenotypically and functionally heterogeneous mouse mucosal-associated invariant T cells using MR1 tetramers. *Journal of Experimental Medicine* 2015; **212**(7): 1095-1108.
21. Le Bourhis L, Martin E, Peguillet I, Guihot A, Froux N, Core M *et al.* Antimicrobial activity of mucosal-associated invariant T cells. *Nature immunology* 2010; **11**(8): 701-8.
22. Hansen TH, Huang S, Arnold PL, Fremont DH. Patterns of nonclassical MHC antigen presentation. *Nature immunology* 2007; **8**(6): 563-8.
23. Miley MJ, Truscott SM, Yu YY, Gilfillan S, Fremont DH, Hansen TH *et al.* Biochemical features of the MHC-related protein 1 consistent with an immunological function. *Journal of immunology (Baltimore, Md. : 1950)* 2003; **170**(12): 6090-8.
24. Yamaguchi H, Hashimoto K. Association of MR1 protein, an MHC class I-related molecule, with beta(2)-microglobulin. *Biochemical and biophysical research communications* 2002; **290**(2): 722-9.

2018 ICB Special Feature Review – MAIT cells

25. Okamoto N, Kanie O, Huang YY, Fujii R, Watanabe H, Shimamura M. Synthetic alpha-mannosyl ceramide as a potent stimulant for an NKT cell repertoire bearing the invariant Valpha19-Jalpha26 TCR alpha chain. *Chemistry & biology* 2005; **12**(6): 677-83.
26. Shimamura M, Huang YY, Okamoto N, Suzuki N, Yasuoka J, Morita K *et al.* Modulation of Valpha19 NKT cell immune responses by alpha-mannosyl ceramide derivatives consisting of a series of modified sphingosines. *European journal of immunology* 2007; **37**(7): 1836-44.
27. Reantragoon R, Kjer-Nielsen L, Patel O, Chen Z, Illing PT, Bhati M *et al.* Structural insight into MR1-mediated recognition of the mucosal associated invariant T cell receptor. *The Journal of experimental medicine* 2012; **209**(4): 761-74.
28. Huang S, Gilfillan S, Cella M, Miley MJ, Lantz O, Lybarger L *et al.* Evidence for MR1 antigen presentation to mucosal-associated invariant T cells. *The Journal of biological chemistry* 2005; **280**(22): 21183-93.
29. Garboczi DN, Hung DT, Wiley DC. HLA-A2-peptide complexes: refolding and crystallization of molecules expressed in *Escherichia coli* and complexed with single antigenic peptides. *Proceedings of the National Academy of Sciences of the United States of America* 1992; **89**(8): 3429-33.
30. Kjer-Nielsen L, Patel O, Corbett AJ, Le Nours J, Meehan B, Liu L *et al.* MR1 presents microbial vitamin B metabolites to MAIT cells. *Nature* 2012; **491**(7426): 717-23.
31. Off MK, Steindal AE, Porojnicu AC, Juzeniene A, Vorobey A, Johnsson A *et al.* Ultraviolet photodegradation of folic acid. *Journal of photochemistry and photobiology. B, Biology* 2005; **80**(1): 47-55.
32. Chua WJ, Kim S, Myers N, Huang S, Yu L, Fremont DH *et al.* Endogenous MHC-related protein 1 is transiently expressed on the plasma membrane in a conformation that activates mucosal-associated invariant T cells. *Journal of immunology (Baltimore, Md. : 1950)* 2011; **186**(8): 4744-50.
33. Ljunggren HG, Stam NJ, Ohlen C, Neeffjes JJ, Hoglund P, Heemels MT *et al.* Empty MHC class I molecules come out in the cold. *Nature* 1990; **346**(6283): 476-80.
34. Juzeniene A, Grigalavicius M, Ma LW, Juraleviciute M. Folic acid and its photoproducts, 6-formylpterin and pterin-6-carboxylic acid, as generators of reactive oxygen species in skin cells during UVA exposure. *Journal of photochemistry and photobiology. B, Biology* 2016; **155**: 116-21.
35. McWilliam HE, Eckle SB, Theodossis A, Liu L, Chen Z, Wubben JM *et al.* The intracellular pathway for the presentation of vitamin B-related antigens by the antigen-presenting molecule MR1. *Nature immunology* 2016; **17**(5): 531-7.
36. Patel O, Kjer-Nielsen L, Le Nours J, Eckle SB, Birkinshaw R, Beddoe T *et al.* Recognition of vitamin B metabolites by mucosal-associated invariant T cells. *Nature communications* 2013; **4**: 2142.

2018 ICB Special Feature Review – MAIT cells

37. Eckle SB, Birkinshaw RW, Kostenko L, Corbett AJ, McWilliam HE, Reantragoon R *et al.* A molecular basis underpinning the T cell receptor heterogeneity of mucosal-associated invariant T cells. *The Journal of experimental medicine* 2014; **211**(8): 1585-600.
38. Keller AN, Eckle SB, Xu W, Liu L, Hughes VA, Mak JY *et al.* Drugs and drug-like molecules can modulate the function of mucosal-associated invariant T cells. *Nature immunology* 2017; **18**(4): 402-411.
39. Corbett AJ, Eckle SB, Birkinshaw RW, Liu L, Patel O, Mahony J *et al.* T-cell activation by transitory neo-antigens derived from distinct microbial pathways. *Nature* 2014; **509**(7500): 361-5.
40. Bacher A, Eberhardt S, Fischer M, Kis K, Richter G. Biosynthesis of vitamin b2 (riboflavin). *Annual review of nutrition* 2000; **20**: 153-67.
41. Vitreschak AG, Rodionov DA, Mironov AA, Gelfand MS. Regulation of riboflavin biosynthesis and transport genes in bacteria by transcriptional and translational attenuation. *Nucleic acids research* 2002; **30**(14): 3141-51.
42. Hartmann N, McMurtrey C, Sorensen ML, Huber ME, Kurapova R, Coleman FT *et al.* Riboflavin Metabolism Variation Among Clinical Isolates of *Streptococcus pneumoniae* Results in Differential Activation of MAIT Cells. *American journal of respiratory cell and molecular biology* 2018.
43. Kurioka A, van Wilgenburg B, Javan RR, Hoyle R, van Tonder AJ, Harrold CL *et al.* Diverse *Streptococcus pneumoniae* strains drive a MAIT cell response through MR1-dependent and cytokine-driven pathways. *The Journal of infectious diseases* 2017.
44. Brutinel ED, Dean AM, Gralnick JA. Description of a riboflavin biosynthetic gene variant prevalent in the phylum Proteobacteria. *Journal of bacteriology* 2013; **195**(24): 5479-86.
45. Fischer M, Bacher A. Biosynthesis of vitamin B2 in plants. *Physiologia Plantarum* 2006; **126**(3): 304-318.
46. Herz S, Eberhardt S, Bacher A. Biosynthesis of riboflavin in plants. The *ribA* gene of *Arabidopsis thaliana* specifies a bifunctional GTP cyclohydrolase II/3,4-dihydroxy-2-butanone 4-phosphate synthase. *Phytochemistry* 2000; **53**(7): 723-31.
47. Sa N, Rawat R, Thornburg C, Walker KD, Roje S. Identification and characterization of the missing phosphatase on the riboflavin biosynthesis pathway in *Arabidopsis thaliana*. *The Plant journal : for cell and molecular biology* 2016; **88**(5): 705-716.
48. Burgess C, O'Connell-Motherway M, Sybesma W, Hugenholtz J, van Sinderen D. Riboflavin production in *Lactococcus lactis*: potential for in situ production of vitamin-enriched foods. *Appl Environ Microbiol* 2004; **70**(10): 5769-77.
49. Soudais C, Samassa F, Sarkis M, Le Bourhis L, Bessoles S, Blanot D *et al.* In Vitro and In Vivo Analysis of the Gram-Negative Bacteria-Derived Riboflavin Precursor Derivatives Activating Mouse MAIT Cells. *Journal of immunology (Baltimore, Md. : 1950)* 2015.

2018 ICB Special Feature Review – MAIT cells

50. Cushman M, Yang D, Gerhardt S, Huber R, Fischer M, Kis K *et al.* Design, synthesis, and evaluation of 6-carboxyalkyl and 6-phosphonoxyalkyl derivatives of 7-oxo-8-ribitylaminolumazines as inhibitors of riboflavin synthase and lumazine synthase. *The Journal of organic chemistry* 2002; **67**(16): 5807-16.
51. Kis K, Kugelbrey K, Bacher A. Biosynthesis of riboflavin. The reaction catalyzed by 6,7-dimethyl-8-ribityllumazine synthase can proceed without enzymatic catalysis under physiological conditions. *The Journal of organic chemistry* 2001; **66**(8): 2555-9.
52. Eckle SB, Corbett AJ, Keller AN, Chen Z, Godfrey DI, Liu L *et al.* Recognition of Vitamin B Precursors and Byproducts by Mucosal Associated Invariant T Cells. *The Journal of biological chemistry* 2015; **290**(51): 30204-11.
53. Mak JY, Xu W, Reid RC, Corbett AJ, Meehan BS, Wang H *et al.* Stabilizing short-lived Schiff base derivatives of 5-aminouracils that activate mucosal-associated invariant T cells. *Nature communications* 2017; **8**: 14599.
54. Hughes AL, Nei M. Pattern of nucleotide substitution at major histocompatibility complex class I loci reveals overdominant selection. *Nature* 1988; **335**(6186): 167-70.
55. Wucherpfennig KW, Allen PM, Celada F, Cohen IR, De Boer R, Garcia KC *et al.* Polyspecificity of T cell and B cell receptor recognition. *Seminars in immunology* 2007; **19**(4): 216-24.
56. Godfrey DI, Uldrich AP, McCluskey J, Rossjohn J, Moody DB. The burgeoning family of unconventional T cells. *Nature immunology* 2015; **16**(11): 1114-23.
57. Gherardin NA, Keller AN, Woolley RE, Le Nours J, Ritchie DS, Neeson PJ *et al.* Diversity of T Cells Restricted by the MHC Class I-Related Molecule MR1 Facilitates Differential Antigen Recognition. *Immunity* 2016; **44**(1): 32-45.
58. Gold MC, McLaren JE, Reistetter JA, Smyk-Pearson S, Ladell K, Swarbrick GM *et al.* MR1-restricted MAIT cells display ligand discrimination and pathogen selectivity through distinct T cell receptor usage. *The Journal of experimental medicine* 2014; **211**(8): 1601-10.
59. Young MH, U'Ren L, Huang S, Mallevaey T, Scott-Browne J, Crawford F *et al.* MAIT cell recognition of MR1 on bacterially infected and uninfected cells. *PloS one* 2013; **8**(1): e53789.
60. Meermeier EW, Laugel BF, Sewell AK, Corbett AJ, Rossjohn J, McCluskey J *et al.* Human TRAV1-2-negative MR1-restricted T cells detect *S. pyogenes* and alternatives to MAIT riboflavin-based antigens. *Nature communications* 2016; **7**: 12506.
61. Lepore M, Kalinichenko A, Calogero S, Kumar P, Paleja B, Schmalzer M *et al.* Functionally diverse human T cells recognize non-microbial antigens presented by MR1. *eLife* 2017; **6**.
62. Georgel P, Radosavljevic M, Macquin C, Bahram S. The non-conventional MHC class I MR1 molecule controls infection by *Klebsiella pneumoniae* in mice. *Molecular immunology* 2011; **48**(5): 769-75.

2018 ICB Special Feature Review – MAIT cells

63. Meierovics A, Yankelevich WJ, Cowley SC. MAIT cells are critical for optimal mucosal immune responses during in vivo pulmonary bacterial infection. *Proceedings of the National Academy of Sciences of the United States of America* 2013; **110**(33): E3119-28.
64. Chua WJ, Truscott SM, Eickhoff CS, Blazevic A, Hoft DF, Hansen TH. Polyclonal mucosa-associated invariant T cells have unique innate functions in bacterial infection. *Infection and immunity* 2012; **80**(9): 3256-67.
65. Gherardin NA, Loh L, Admojo L, Davenport AJ, Richardson K, Rogers A *et al.* Enumeration, functional responses and cytotoxic capacity of MAIT cells in newly diagnosed and relapsed multiple myeloma. *Scientific reports* 2018; **8**(1): 4159.
66. D'Souza C, Pediongo T, Wang H, Scheerlinck JY, Kostenko L, Esterbauer R *et al.* Mucosal-Associated Invariant T Cells Augment Immunopathology and Gastritis in Chronic *Helicobacter pylori* Infection. *Journal of immunology (Baltimore, Md. : 1950)* 2018.
67. Magalhaes I, Pingris K, Poitou C, Bessoles S, Venteclef N, Kiaf B *et al.* Mucosal-associated invariant T cell alterations in obese and type 2 diabetic patients. *The Journal of clinical investigation* 2015; **125**(4): 1752-62.
68. Rouxel O, Da Silva J, Beaudoin L, Nel I, Tard C, Cagninacci L *et al.* Cytotoxic and regulatory roles of mucosal-associated invariant T cells in type 1 diabetes. *Nature immunology* 2017; **18**(12): 1321-1331.
69. Koay HF, Gherardin NA, Enders A, Loh L, Mackay LK, Almeida CF *et al.* A three-stage intrathymic development pathway for the mucosal-associated invariant T cell lineage. *Nature immunology* 2016; **17**(11): 1300-1311.
70. Gherardin NA, Souter MNT, Koay HF, Mangas KM, Seemann T, Stinear TP *et al.* Human blood MAIT cell subsets defined using MR1 tetramers. *Immunology and cell biology* 2018.
71. Ben Youssef G, Tourret M, Salou M, Ghazarian L, Houdouin V, Mondot S *et al.* Ontogeny of human mucosal-associated invariant T cells and related T cell subsets. *The Journal of experimental medicine* 2018; **215**(2): 459-479.
72. Dias J, Leeansyah E, Sandberg JK. Multiple layers of heterogeneity and subset diversity in human MAIT cell responses to distinct microorganisms and to innate cytokines. *Proceedings of the National Academy of Sciences of the United States of America* 2017; **114**(27): E5434-e5443.
73. Liuzzi AR, Kift-Morgan A, Lopez-Anton M, Friberg IM, Zhang J, Brook AC *et al.* Unconventional Human T Cells Accumulate at the Site of Infection in Response to Microbial Ligands and Induce Local Tissue Remodeling. *Journal of immunology (Baltimore, Md. : 1950)* 2016; **197**(6): 2195-207.
74. Cosgrove C, Ussher JE, Rauch A, Gartner K, Kurioka A, Huhn MH *et al.* Early and nonreversible decrease of CD161⁺⁺ /MAIT cells in HIV infection. *Blood* 2013; **121**(6): 951-61.

2018 ICB Special Feature Review – MAIT cells

75. D'Souza C, Pediongco T, Wang H, Scheerlinck JY, Kostenko L, Esterbauer R *et al.* Mucosal-Associated Invariant T Cells Augment Immunopathology and Gastritis in Chronic *Helicobacter pylori* Infection. *Journal of immunology (Baltimore, Md. : 1950)* 2018; **200**(5): 1901-1916.
76. Dias J, Sandberg JK, Leeansyah E. Extensive Phenotypic Analysis, Transcription Factor Profiling, and Effector Cytokine Production of Human MAIT Cells by Flow Cytometry. *Methods in molecular biology (Clifton, N.J.)* 2017; **1514**: 241-256.
77. Dias J, Sobkowiak MJ, Sandberg JK, Leeansyah E. Human MAIT-cell responses to *Escherichia coli*: activation, cytokine production, proliferation, and cytotoxicity. *Journal of leukocyte biology* 2016; **100**(1): 233-40.
78. Gibbs A, Leeansyah E, Introini A, Paquin-Proulx D, Hasselrot K, Andersson E *et al.* MAIT cells reside in the female genital mucosa and are biased towards IL-17 and IL-22 production in response to bacterial stimulation. *Mucosal immunology* 2017; **10**(1): 35-45.
79. Jeffery HC, van Wilgenburg B, Kurioka A, Parekh K, Stirling K, Roberts S *et al.* Biliary epithelium and liver B cells exposed to bacteria activate intrahepatic MAIT cells through MR1. *Journal of hepatology* 2016; **64**(5): 1118-1127.
80. Jiang J, Wang X, An H, Yang B, Cao Z, Liu Y *et al.* Mucosal-associated invariant T-cell function is modulated by programmed death-1 signaling in patients with active tuberculosis. *American journal of respiratory and critical care medicine* 2014; **190**(3): 329-39.
81. Jo J, Tan AT, Ussher JE, Sandalova E, Tang XZ, Tan-Garcia A *et al.* Toll-like receptor 8 agonist and bacteria trigger potent activation of innate immune cells in human liver. *PLoS pathogens* 2014; **10**(6): e1004210.
82. Kim JS, Kang MJ, Kim WS, Han SJ, Kim HM, Kim HW *et al.* Essential engagement of Toll-like receptor 2 in initiation of early protective Th1 response against rough variants of *Mycobacterium abscessus*. *Infection and immunity* 2015; **83**(4): 1556-67.
83. Kurioka A, Jahun AS, Hannaway RF, Walker LJ, Fergusson JR, Sverremark-Ekstrom E *et al.* Shared and Distinct Phenotypes and Functions of Human CD161⁺⁺ Valpha7.2⁺ T Cell Subsets. *Frontiers in immunology* 2017; **8**: 1031.
84. Kurioka A, Ussher JE, Cosgrove C, Clough C, Fergusson JR, Smith K *et al.* MAIT cells are licensed through granzyme exchange to kill bacterially sensitized targets. *Mucosal immunology* 2015; **8**(2): 429-40.
85. Kwon YS, Cho YN, Kim MJ, Jin HM, Jung HJ, Kang JH *et al.* Mucosal-associated invariant T cells are numerically and functionally deficient in patients with mycobacterial infection and reflect disease activity. *Tuberculosis (Edinburgh, Scotland)* 2015; **95**(3): 267-74.
86. Le Bourhis L, Dusseaux M, Bohineust A, Bessoles S, Martin E, Premel V *et al.* MAIT cells detect and efficiently lyse bacterially-infected epithelial cells. *PLoS pathogens* 2013; **9**(10): e1003681.

2018 ICB Special Feature Review – MAIT cells

87. Leeansyah E, Ganesh A, Quigley MF, Sonnerborg A, Andersson J, Hunt PW *et al.* Activation, exhaustion, and persistent decline of the antimicrobial MR1-restricted MAIT-cell population in chronic HIV-1 infection. *Blood* 2013; **121**(7): 1124-35.
88. Leeansyah E, Loh L, Nixon DF, Sandberg JK. Acquisition of innate-like microbial reactivity in mucosal tissues during human fetal MAIT-cell development. *Nature communications* 2014; **5**: 3143.
89. Leeansyah E, Svard J, Dias J, Buggert M, Nystrom J, Quigley MF *et al.* Arming of MAIT Cell Cytolytic Antimicrobial Activity Is Induced by IL-7 and Defective in HIV-1 Infection. *PLoS pathogens* 2015; **11**(8): e1005072.
90. Loh L, Wang Z, Sant S, Koutsakos M, Jegaskanda S, Corbett AJ *et al.* Human mucosal-associated invariant T cells contribute to antiviral influenza immunity via IL-18-dependent activation. *Proceedings of the National Academy of Sciences of the United States of America* 2016; **113**(36): 10133-8.
91. Salerno-Goncalves R, Rezwani T, Sztein MB. B cells modulate mucosal associated invariant T cell immune responses. *Frontiers in immunology* 2014; **4**: 511.
92. Salio M, Gasser O, Gonzalez-Lopez C, Martens A, Veerapen N, Gileadi U *et al.* Activation of Human Mucosal-Associated Invariant T Cells Induces CD40L-Dependent Maturation of Monocyte-Derived and Primary Dendritic Cells. *Journal of immunology (Baltimore, Md. : 1950)* 2017; **199**(8): 2631-2638.
93. Shaler CR, Choi J, Rudak PT, Memarnejadian A, Szabo PA, Tun-Abraham ME *et al.* MAIT cells launch a rapid, robust and distinct hyperinflammatory response to bacterial superantigens and quickly acquire an anergic phenotype that impedes their cognate antimicrobial function: Defining a novel mechanism of superantigen-induced immunopathology and immunosuppression. *PLoS biology* 2017; **15**(6): e2001930.
94. Solders M, Gorchs L, Erkers T, Lundell AC, Nava S, Gidlof S *et al.* MAIT cells accumulate in placental intervillous space and display a highly cytotoxic phenotype upon bacterial stimulation. *Scientific reports* 2017; **7**(1): 6123.
95. Ussher JE, Bilton M, Attwod E, Shadwell J, Richardson R, de Lara C *et al.* CD161⁺⁺ CD8⁺ T cells, including the MAIT cell subset, are specifically activated by IL-12+IL-18 in a TCR-independent manner. *European journal of immunology* 2014; **44**(1): 195-203.
96. Ussher JE, van Wilgenburg B, Hannaway RF, Ruustal K, Phalora P, Kurioka A *et al.* TLR signalling in human antigen-presenting cells regulates MR1-dependent activation of MAIT cells. *European journal of immunology* 2016.
97. Meierovics AI, Cowley SC. MAIT cells promote inflammatory monocyte differentiation into dendritic cells during pulmonary intracellular infection. *The Journal of experimental medicine* 2016; **213**(12): 2793-2809.
98. Booth JS, Salerno-Goncalves R, Blanchard TG, Patil SA, Kader HA, Safta AM *et al.* Mucosal-Associated Invariant T Cells in the Human Gastric Mucosa and Blood: Role in *Helicobacter pylori* Infection. *Frontiers in immunology* 2015; **6**: 466.

2018 ICB Special Feature Review – MAIT cells

99. Sharma PK, Wong EB, Napier RJ, Bishai WR, Ndung'u T, Kasproicz VO *et al.* High expression of CD26 accurately identifies human bacteria-reactive MR1-restricted MAIT cells. *Immunology* 2015; **145**(3): 443-53.
100. Gold MC, Eid T, Smyk-Pearson S, Eberling Y, Swarbrick GM, Langley SM *et al.* Human thymic MR1-restricted MAIT cells are innate pathogen-reactive effectors that adapt following thymic egress. *Mucosal immunology* 2013; **6**(1): 35-44.
101. Harriff MJ, Cansler ME, Toren KG, Canfield ET, Kwak S, Gold MC *et al.* Human lung epithelial cells contain Mycobacterium tuberculosis in a late endosomal vacuole and are efficiently recognized by CD8(+) T cells. *PloS one* 2014; **9**(5): e97515.
102. Jiang J, Yang B, An H, Wang X, Liu Y, Cao Z *et al.* Mucosal-associated invariant T cells from patients with tuberculosis exhibit impaired immune response. *The Journal of infection* 2016; **72**(3): 338-52.
103. Salerno-Goncalves R, Luo D, Fresnay S, Magder L, Darton TC, Jones C *et al.* Challenge of Humans with Wild-type Salmonella enterica Serovar Typhi Elicits Changes in the Activation and Homing Characteristics of Mucosal-Associated Invariant T Cells. *Frontiers in immunology* 2017; **8**: 398.
104. Howson LJ, Napolitani G, Shepherd D, Ghadbane H, Kurupati P, Preciado-Llanes L *et al.* MAIT cell clonal expansion and TCR repertoire shaping in human volunteers challenged with Salmonella Paratyphi A. *Nature communications* 2018; **9**(1): 253.

2018 ICB Special Feature Review – MAIT cells

Table 1a

Microbes that activate MAIT cells	Expansion or activation <i>in vitro</i> (and MR1 dependency)	Expansion or activation <i>in vivo</i>	Riboflavin pathway based on KEGG pathway database (and knock-outs)	Reference
<i>Bacteroides thetaiotaomicron</i>	ND	X	X	21
<i>Bifidobacterium animalis</i>	ND	X	No*	21
<i>Candida albicans</i>	X(X)	X	X	21,38,60,72
<i>Candida glabrata</i>	X(X)	ND	X	21
<i>Corynebacterium striatum</i>	X(X)	ND	X	73
<i>Escherichia coli</i>	X (X)	X ⁺	X(X)	4, 13, 21, 27, 39, 49, 99, 12-96
<i>Enterobacter cloacae</i>	ND	X	X	21
<i>Francisella tularensis</i>	X(X)	X ⁺	X	63,97
<i>Helicobacter pylori</i>	X(X)	X ⁺	X	75,98
<i>Klebsiella pneumoniae</i>	X(X)	X	X	21,27,62,73,93
<i>Lactobacillus acidophilus</i>	X	X	No*	21
<i>Lactobacillus casei</i>	ND	X	No*	21
<i>Lactococcus lactis</i>	X(X)	ND	X(X)	39
<i>Mycobacterium abscessus</i>	X(X)	X	X	21
<i>Mycobacterium avium</i>	X	ND	X	60
<i>Mycobacterium bovis</i>	X(X)	X ⁺	X	13,64,80
<i>Mycobacterium smegmatis</i>	X(X)	ND	X	58,60,99
<i>Mycobacterium tuberculosis</i>	X(X)	ND	X	2, 60, 80, 100-102
<i>Neisseria gonorrhoeae</i>	X	ND	X	60
<i>Nocardia asteroides</i>	X	ND	X**	60
<i>Pseudomonas aeruginosa</i>	X (X)	X	X	18,21,27,60,73,81,93
<i>Saccharomyces cerevisiae</i>	X(X)	ND	X	21

2018 ICB Special Feature Review – MAIT cells

<i>Salmonella enterica</i> serovar Typhimurium	X(X)	X [†]	X(X)	2, 5, 19, 27, 30, 39, 58, 60, 86, 91, 91, 103
<i>Salmonella enterica</i> serovar Paratyphi A	X(X)	X	X	104
<i>Shigella flexneri</i>	X(X)	ND	X	60, 86
<i>Staphylococcus aureus</i>	X	X	X	2, 4, 21, 60, 73
<i>Staphylococcus epidermidis</i>	X(X)	X	X	21, 27
<i>Streptococcus pneumoniae</i>	X(X)	X	X	43, 44
<i>Streptococcus pyogenes</i>	X(X)	ND	No	60
<i>Vibrio parahaemolyticus</i>	X	ND	X	60
<i>Yersinia enterocolitica</i>	X	ND	X	60

*Intact KEGG riboflavin synthesis pathways have not been documented in the strains tested to date.

**Species not listed in the KEGG pathway database but other species of the same genus feature the riboflavin pathway.

†Mild MAIT cell accumulation *in vivo*.

‡Strong MAIT cell accumulation *in vivo*.

ND No data available.

Table 1b

Microbes that do not activate MAIT cells	Reference
<i>Streptococcus</i> group A	21
<i>Enterococcus faecalis</i>	21, 39, 60, 73, 81, 95, 96
<i>Listeria monocytogenes</i>	2, 4, 73, 91

Page 6: [1] Deleted

IMB IMB

3/21/18 12:33:00 AM

Page 6: [2] Deleted

IMB IMB

3/21/18 12:39:00 AM